Investment, Funding & Disinvestments

Unlike previous Ebola epidemics caused by the Zaire strain, the current Bundibugyo outbreak has no licensed vaccine or approved treatment, making research an urgent public health priority.

Biogen has paused or discontinued funding for most of Apellis’ legacy research portfolio while conducting a comprehensive review of the acquired company’s clinical and preclinical assets.

The acquisition gives Zymeworks access to Yupelri, an FDA-approved, once-daily nebulized maintenance therapy for chronic obstructive pulmonary disease (COPD) that Theravance markets in partnership with Viatris.

The expanded facility will combine inpatient rehabilitation, outpatient specialty clinics, orthopaedic and musculoskeletal care, neurosciences, sports medicine, physical medicine, and cardiac rehabilitation within a single coordinated care model.

Closing this gap would benefit not only patients but also their families and healthcare systems while supporting the Gulf’s broader vision of compassionate, patient-centred care.

Gavi has indicated that proposals involving vaccine production in Africa will receive particular consideration as part of broader efforts to strengthen regional manufacturing capacity.

The transaction drew robust interest from both regional and international investors, with the orderbook reaching approximately US$1.6 billion, making the offering about 3.2 times oversubscribed.

The agreement establishes a formal gateway between Abu Dhabi and California, creating new opportunities for collaboration across research, innovation, investment, and commercialization.

Developed through a partnership between Masdar City, M42, and Attentive Science, Biosphere Labs aims to address one of the biggest challenges facing researchers and biotechnology companies: access to high-quality laboratory infrastructure.

Antares will lead the research phase and apply its proprietary drug-discovery platform to a limited number of oncology targets before Novartis decides whether to exercise licensing options for individual programmes.